Cellectis S.A. CLLS
Annual
Quarterly
FY2025 · ended Dec 31, 2025 · Revenue $72.95M, +75.8% YoY · Filed Mar 20, 2026
Cellectis S.A. (CLLS) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $72.9 million and a net loss of $67.6 million. Free cash flow was -$41.8 million. As of Dec 31, 2025 it held $61.5 million in cash and investments and $35.4 million in total debt.
Revenue
$72.95M
+75.8% vs prior year
Net income
$-67.59M
-83.9% vs prior year
Operating cash flow
$-39.40M
-271.4% vs prior year
Free cash flow
$-41.76M
-304.7% vs prior year
EPS
$-0.67
-63.4% vs prior year
Dividend per share
None
Shares outstanding
100.34M
+0.2% vs prior year
Net cash
$26.11M
FY 2025
Operating margin
-45.3%
FY 2025
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CLLS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- France
- Headquarters
- Paris, Lle-De-France
- SEC filer status
- Accelerated filer
- SEC CIK
- 1627281
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $72.9M | $41.5M | $755,000 | $19.2M | $30.3M |
| Operating income | -$33.1M | -$59.6M | -$97.3M | -$89.7M | -$103.5M |
| Net income | -$67.6M | -$36.8M | -$108.4M | -$114.0M | -$125.1M |
| Diluted EPS | -$0.67 | -$0.41 | -$1.77 | -$2.33 | -$2.55 |
| Operating cash flow | -$39.4M | $23.0M | -$24.7M | -$87.4M | -$104.6M |
| Free cash flow | -$41.8M | $20.4M | -$25.8M | -$89.9M | -$123.1M |
| Total assets | $324.7M | $383.5M | $334.3M | $261.2M | $382.1M |
| Total liabilities | $248.8M | $252.5M | — | — | — |
| Stockholders' equity | $75.9M | $131.0M | $84.7M | $125.9M | $236.5M |
| Cash and investments | $61.5M | $143.3M | $136.7M | $93.2M | $185.6M |
| Total debt | $35.4M | $42.6M | $51.5M | $57.2M | $79.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Oct 28, 2026 | Oct 27, 2026 |
| 6-K | Current report (foreign issuer) | Sep 14, 2026 | Sep 14, 2026 |
| 6-K | Current report (foreign issuer) | Sep 11, 2026 | Sep 11, 2026 |
| 6-K/A | Filing | Sep 11, 2026 | Jun 30, 2026 |
| 6-K | Current report (foreign issuer) | Sep 1, 2026 | Sep 1, 2026 |
| 6-K | Current report (foreign issuer) | Aug 6, 2026 | Aug 6, 2026 |
All 534 Cellectis S.A. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.